Brez internetne povezave — prikazana je shranjena različica strani.

Arrowhead Pharmac…

USUSD
← Na filter delnic

Arrowhead Pharmaceuticals Inc (US:ARWR) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 2. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O podjetju

Spletna stran
arrowheadpharma.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Sedež
Pasadena, United States
Izvršni direktor
Dr. Christopher R. Anzalone Ph.D.
Zaposleni
711
Ustanovljena
2004
Delnice v obtoku
141.25 mio. na dan 2026-07-30
Prosto prenosljive delnice
122.45 mio.
Tržna kapitalizacija
9.22 mrd. USD
Notranje osebe
3.66%
Institucionalni vlagatelji
85.47%
Panoga (SIC)
Pharmaceutical Preparations
ISIN
US04280A1007
LEI
549300O3CSB8T7OZ3D66
Opis

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Borze in oznake

BorzaOznakaValutaCenaVrsta
US USA StocksARWR glavnaUSD60.74 -1.20%navadne delnice
LSE London Stock Exchange0HI3 IOBUSD65.82 +0.00%navadne delnice

Cena v 3 mesecih

dan rasti dan padca ex-dividendni datum datum izplačilaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Dividende

Ni bilo najdenih izplačil dividend (preverjeno 09.10.2026). Podjetje verjetno ne izplačuje dividend.

Novice ta teden

Novic s spletnega mesta podjetja še ni.

oglas

Največji imetniki

ImetnikDeležDelniceDatum poročila
Blackrock Inc.10.53%14.83 mio.2026-06-30
Avoro Capital Advisors L…8.06%11.36 mio.2026-06-30
FMR, LLC5.71%8.04 mio.2026-06-30
Vanguard Portfolio Manag…4.51%6.35 mio.2026-06-30
Vanguard Capital Managem…4.34%6.11 mio.2026-06-30
State Street Corporation4.04%5.69 mio.2026-06-30
iShares Trust-iShares Co…3.5%4.93 mio.2026-08-31
VANGUARD INDEX FUNDS-Van…3.01%4.25 mio.2026-06-30
NORGES BANK2.77%3.9 mio.2026-06-30
Invesco Ltd.2.76%3.88 mio.2026-06-30
ANZALONE CHRISTOPHER RIC…≈2.69%3.79 mio.2026-01-02
Geode Capital Management…2.51%3.53 mio.2026-06-30
Fred Alger Management, L…2.34%3.3 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.18%3.07 mio.2026-06-30
Fidelity Mt. Vernon Stre…1.81%2.55 mio.2026-07-31
Invesco Exchange-Traded…1.27%1.79 mio.2026-08-31
VANGUARD INDEX FUNDS-Van…1.26%1.77 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%1.61 mio.2026-06-30
SPDR SERIES TRUST-State…1.05%1.48 mio.2026-08-31
SPDR S&P MIDCAP 400 ETF…0.73%1.03 mio.2026-08-31
iShares Trust-iShares Bi…0.69%968 7382026-07-31
O'BRIEN PATRICK C (Chief…≈0.39%547 4082026-01-06
MYSZKOWSKI KENNETH ALLEN…≈0.32%455 4332025-01-07
HAMILTON JAMES C (Office…≈0.16%226 9582026-04-23
APEL DANIEL JOSEPH (Chie…≈0.12%162 9052026-04-22
GIVEN DOUGLAS BRUCE (Dir…≈0.09%124 1672024-12-17
PERRY MICHAEL S (Directo…≈0.08%111 4592026-08-18
FERRARI MAURO (Director)≈0.05%69 0532025-12-26
WADDILL WILLIAM D (Direc…≈0.04%56 5632025-12-19
LU HONGBO B (Director)≈0.04%52 0122026-05-12